secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001193125-23-147301
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions amends credit facility, extends maturity to 2025, reduces revolver to $300M
--------------------------------------------------------------------------------

- Extended maturity from Oct 2023 to May 2025; reduced revolver from $600M to $300M.
- Used $270M from travel health sale to Bavarian Nordic plus $217.2M cash to repay $144.4M term loan and $342.8M revolver.
- New covenants: debt service coverage min 2.25x, leverage max 4.50x, must raise $75M equity/unsecured debt by Apr 2024.
- Interest rate margin set at 6.00% through Mar 2024, then 2.75%-4.00% based on leverage ratio.
- ATM equity offering of up to $150M with Evercore and RBC, commissions up to 3% of gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000119312523147301/0001193125-23-147301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000119312523147301/d499270d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-147301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer